Liquid cytology test + CINtec Plus P16/Ki67

• It's best to perform the test at least 4 days after your last period and no later than 4 days before your period starts. Vaginal medications should not be used for at least 4 days before the test. At least 1 day should have passed since your last gynecological examination/transvaginal ultrasound.
• The test material is a cervical swab collected on a liquid medium.
• The patient should not do any vaginal rinsing or have sexual intercourse for 24 hours before the examination.

We do not accept samples from outside.

Liquid-Based Cytology (LBC) is a modern technique for preparing cytological slides that reduces errors, improves the quality of slides, and allows for multiple tests to be performed from a single sample.
In this method, a smear collected from the cervix using a cytological brush is preserved in a special fluid and delivered to the laboratory in this manner. The brush tip is placed in the container along with the material, ensuring that it reaches the laboratory intact without any loss, unlike a standard smear.
The fluid in which the material is stored allows the cell shape to be preserved while simultaneously removing mucus, yeast cells, bacteria, and cells that can appear in inflammatory conditions.
Liquid-based cytology is more accurate in detecting both precancerous conditions and cancer cells themselves, while simultaneously reducing the number of necessary tests.
A major advantage of the LBC technique is the ability to perform additional diagnostic tests on the same sample without the need to recall the patient, thanks to the material being stored in a special fluid (HPV, Chlamydia trachomatis).
Unlike traditional methods, LBC testing can be performed less frequently, i.e., once every three years.
The Cintec Plus test is performed to further diagnose precancerous lesions and cervical cancer when the Pap smear result is abnormal or inconclusive.
Cervical cancer is the second most common cancer worldwide.
Approximately 3,500 cases are diagnosed in Poland each year, with half of these patients dying due to late diagnosis. One of the leading causes of cervical cancer is the human papillomavirus (HPV). Cervical cancer is a malignant tumor that develops from the epithelium covering the cervix or cervical canal. To date, approximately 200 types of the virus have been identified, but only a subset are sexually transmitted and are associated with high-grade dysplasia and cervical cancer. Due to their varying oncogenic potential, high-risk (HR) HPV viruses—HPV 16, HPV 18, HPV 31, HPV 33, and HPV 45—are associated with over 80% of precancerous cervical cancer cases, and low-risk (LR) HPV viruses—HPV 6 and HPV 11, which are associated with benign, lower-grade intraepithelial lesions or the development of genital warts.
Acute infection with a high-risk HPV virus triggers the expression of viral genes in mature epithelial cells and disrupts their cell cycle. Uncontrolled cell proliferation occurs, which is reflected in the production of the p16 and ki-67 proteins, known as biomarkers of infection.
The p16 protein plays a key role in cell cycle control, and the Ki-67 protein is a cell proliferation protein.
The CINtec plus test detects both of these proteins, allowing for the detection of cancerous changes at the cellular level at a very early stage of their development. The test is characterized by high sensitivity and specificity.
The p16/Ki-67 test, combined with a Pap smear and HPV test, is crucial for making the most accurate diagnosis and interpretation of difficult cases such as ASCUS, LSIL, ASC-H, or glandular lesions.
The most comprehensive, reliable, and sensitive method for testing for cervical cancer is a liquid-based cytology test (LBC) supplemented with HPV and CINtec plus.
The combination of these three diagnostic tests is particularly important when the result of a cytological test is abnormal or difficult to interpret.

Enter one-time code:Show
Invalid code entered. Please try again.